Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Beam Therapeutics Inc.

NASDAQ: BEAM · Life Sciences · 3 alerts · CIK 1745999

Share price
$20.94Close, Nov 16
Market cap
$2.17B
Shares outstanding
103.5MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Beam Therapeutics Inc. filings on SEC EDGAR ↗

8:38 AM ET 10-Q
Financial Results

Beam Therapeutics Q3 2026 Results: Net Loss of $134M, Loss Widens

Beam Therapeutics reported a net loss of $351.4 million for the nine months ended September 30, 2026, compared to $323.0 million in the prior year. Total assets decreased to $1.27 billion from $1.48 billion at year-end 2025, while the company recognized $32.5 million in license and collaboration revenue during the first nine months of 2026.

Key figure
Net loss $134M
8:37 AM ET 8-K
Financial Results

Beam Therapeutics Financial Results

Beam Therapeutics reported third quarter 2026 financial results, ending the period with $1.0 billion in cash and marketable securities. The company highlighted clinical progress across its base editing portfolio, including an expected BLA submission for risto-cel in sickle cell disease as early as year-end 2026 and the anticipated completion of dosing for the BEAM-302 pivotal cohort in the first half of 2027.

Term
Q3 2026

“Our progress this quarter reflects the growing maturity and momentum of Beam’s platform, with predictable clinical translation across four distinct programs and multiple potentially transformative medicines advancing toward patients, bringing our vision for a new era of genetic medicine increasingly within reach.”

John Evans, chief executive officer of Beam Therapeutics

“We are approaching a potential first BLA filing with risto-cel as early as the end of this year, and the pivotal cohort for BEAM-302 is rapidly advancing with completion of dosing expected in the first half of 2027.”

John Evans, chief executive officer of Beam Therapeutics
8:09 PM ET Form 4
Insider Selling

Beam Therapeutics CEO John M. Evans Sells $1.19M of Stock

John M. Evans, CEO, sold 50,000 shares of Beam Therapeutics Inc. at $23.57 to $23.98 a share (average $23.77) in 2 transactions, worth $1.19M in total between Oct 15, 2026 and Oct 16, 2026. Shares held after the trade: 1,047,205 (-2.3%).

Value
$1.19M
Shares
50,000
Average price
$23.77
Role
CEO
Holding change
-2.3%
Trade date
Oct 15, 2026 to Oct 16, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.